News
Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...
Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...
Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...
RAHWAY, N.J. – Merck & Co., Inc., a global healthcare ... particularly in treating challenging forms of ovarian cancer. Currently, KEYTRUDA is not approved for the treatment of ovarian cancer ...
Clinical Trials Arena on MSN6d
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancerMSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...
US pharma giant Merck & Co (NYSE: MRK) today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...
KEYTRUDA ® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS ...
Currently, KEYTRUDA is not approved for the treatment of ovarian cancer, but it has multiple approved indications in the United States for other cancers, including melanoma, non-small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback